COVID-19, according to a small study conducted in the island nation.India's Biocon Ltd said earlier this month it received regulatory approval in India for itolizumab for use in coronavirus infected patients with moderate-to-severe respiratory distress.
It was originally tested as a treatment for psoriasis.Researchers, including from Cuba's Center of Molecular Immunology, which developed itolizumab, said timely use of the drug in combination with standard therapy helped reduce inflammation and prevented COVID-19 from worsening.The 19 hospitalized patients from a single nursing home had tested positive for the virus in April.All were older than age 64 and had chronic health conditions such as hypertension, dementia, heart disease, diabetes.
Read more on livemint.com